PRINCETON, N.J., Nov. 10, 2011 /PRNewswire/ -- Signum Biosciences, Inc., a privately held biotechnology company, has entered into an agreement with GlaxoSmithKline (China) R&D Company Limited (GSK) to collaborate on Signum’s phosphatase screening technology and Phosphoprotein Phosphatase 2A (PP2A).
The agreement provides Signum with research support and milestone payments. GSK receives the exclusive right of Signum’s proprietary phosphatase screening technology for GSK’s research and development activities in neurosciences.
GSK and Signum will undertake a broad R&D collaboration to screen and identify PP2A targeted compounds including those bridging the link between PP2A methylation and tau hyperphosphorylation. Signum’s partnership with GSK furthers Signum’s position as an innovative biotech company, advancing pioneering drug discovery and leveraging GSK’s capabilities in research and development.
Maxwell Stock, President of Signum Biosciences, commented, “GSK is an ideal partner for Signum. We will develop therapeutics using our phosphatase screening technology in an alliance that utilizes the expertise of both companies. We are proud to be working in collaboration with a leading pharmaceutical company in innovative research and development. Collaborations such as these allow partners to share knowledge, expertise and resources and thereby provide a highly effective way of progressing cutting edge research and developing an effective drug.”
About Signum Biosciences, Inc.
Signum, a Princeton, New Jersey- based biotechnology company, dedicated to developing small-molecule therapeutics derived from its Phosphatase platform to modulate signal transduction imbalances. Through research on protein networks that control biological systems, Signum is developing therapeutic agents for Alzheimer’s, Parkinson’s and other neurodegenerative diseases. Signum’s technology provides many opportunities for the development of novel consumer products and pharmaceutical candidates. For further information please visit www.signumbiosciences.com.
SOURCE Signum Biosciences, Inc.
